In the last trading session, 0.41 million 4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares changed hands as the company’s beta touched 2.90. With the company’s per share price at $25.15 changed hands at $0.0 or 0.00% during last session, the market valuation stood at $1.30B. FDMT’s last price was a discount, traded about -44.14% off its 52-week high of $36.25. The share price had its 52-week low at $9.44, which suggests the last value was 62.47% up since then. When we look at 4D Molecular Therapeutics Inc’s average trading volume, we note the 3-month average coming to 613.65K.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
With action -0.75%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 24.14%, with the 5-day performance at -0.75% in the red. However, in the 30-day time frame, 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is 6.88% up.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
Data shows that the 4D Molecular Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 107.68% over the past 6 months, a -16.28% in annual growth rate that is considerably lower than the industry average of 13.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -46.35%. The 2024 estimates are for 4D Molecular Therapeutics Inc earnings to decrease by -11.58%.
FDMT Dividends
4D Molecular Therapeutics Inc is expected to release its next quarterly earnings report in June.
